Histone deacetylase inhibitors: new treatment options for inflammatory joint disease?

Abstract

Histone deacetylase inhibitors (HDIs) are a new class of compounds that are being developed for the treatment of malignancies such as cutaneous T-cell lymphoma. HDIs inhibit the removal of acetyl groups from histones. The histone acetylation process is dependent on two enzymes, histone acetyl transferase (HAT) and histone deacetylase (HDAC), and regulates… (More)
DOI: 10.1016/j.jbspin.2010.03.009

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.